S-1: NeuroBo Pharmaceuticals Files for Resale of Up to 17.2 Million Shares Following Private Placement

NeuroBo Pharmaceuticals has filed a registration statement for the resale of up to 17,175,579 shares of its common stock by selling securityholders, following a recent private placement.

Summary

• NeuroBo Pharmaceuticals has filed a Form S-1 registration statement with the SEC to register the resale of up to 17,175,579 shares of its common stock.
• These shares consist of 2,544,530 PIPE Shares, up to 1,781,171 shares issuable upon exercise of Pre-Funded Warrants, up to 5,089,060 shares issuable upon exercise of Series A Warrants, up to 7,633,591 shares issuable upon exercise of Series B Warrants, and up to 127,227 shares issuable upon exercise of Placement Agent Warrants.
• The warrants were issued in a private placement pursuant to securities purchase agreements dated June 23, 2024.
• The company will not receive any proceeds from the sale of these shares by the selling securityholders, but will receive proceeds from the exercise of any Warrants for cash.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol NRBO, and the last reported sale price on July 17, 2024, was $4.75 per share.
• NeuroBo is a clinical-stage biotechnology company focused on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases, with programs targeting MASH and obesity.
• The company is currently conducting Phase 2a trial of DA-1241 for the treatment of MASH and Phase 1 trial of DA-1726 for the treatment of obesity.
• The company expects to report the full trial data for DA-1241 in the second half of 2024 and top-line data from the SAD Part 1 study of DA-1726 in the third quarter of 2024 and the MAD Part 2 study in the first quarter of 2025.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focused on the registration of shares for resale. While it highlights ongoing clinical trials, it also acknowledges risks associated with stock sales and competition.

Positives

• The registration statement allows selling securityholders to offer and sell their shares, potentially increasing liquidity for investors.
• The company could receive up to approximately $50.6 million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash, which would be used for working capital and general corporate purposes, including to continue the clinical development of DA-1726 for the treatment of obesity.
• The company is advancing its clinical programs for MASH and obesity with ongoing Phase 2a and Phase 1 trials, respectively.

Negatives

• The company will not receive any proceeds from the sale of shares of common stock by the Selling Securityholders.
• Sales of substantial amounts of the company's common stock by a Selling Securityholder or an existing securityholder, or the perception that these sales could occur, could adversely affect the price of the company's common stock.
• The company is a smaller reporting company, which may result in reduced disclosure and potentially a less active trading market for its common stock.

Risks

• Sales of substantial amounts of common stock by selling securityholders could adversely affect the market price.
• The company's reliance on third parties for development and manufacturing poses risks to its clinical trials and product commercialization.
• The company faces substantial competition in the biotechnology industry.
• The company may be required to make significant payments under the license agreement with Dong-A and other existing license agreements.
• The company may never achieve or maintain profitability.

Future Outlook

The company expects to report the full trial data for DA-1241 in the second half of 2024 and top-line data from the SAD Part 1 study of DA-1726 in the third quarter of 2024 and the MAD Part 2 study in the first quarter of 2025.

Industry Context

NeuroBo is operating in the competitive biotechnology industry, focusing on cardiometabolic diseases such as MASH and obesity, which are areas of significant unmet medical need and active research and development.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• However, the company's focus on MASH and obesity aligns with current trends in the pharmaceutical industry, where there is significant investment in developing treatments for these conditions.
• Companies like Viking Therapeutics, Madrigal Pharmaceuticals, and Novo Nordisk are also actively involved in developing therapies for MASH and obesity, and their clinical trial results and market capitalization could serve as benchmarks for NeuroBo.

Related Party Transactions

• Dong-A ST Co., Ltd. is a related party due to the license agreement, securities purchase agreement, shared services agreement, registration rights agreement, and investor rights agreement between the two companies.
• Dong-A has agreed to vote all shares of common stock that it or its affiliates beneficially owns with respect to any proposals related to the Stockholder Approval presented to our stockholders at our next stockholders meeting.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised and the shares are sold into the market.
• The company's ability to fund its clinical programs and operations depends on the exercise of warrants and potential future financing.
• The success of the clinical trials and the commercialization of the product candidates will impact the company's employees, customers, and suppliers.

Next Steps

• The selling securityholders may offer, sell, or distribute the shares of common stock.
• The company is required to use best efforts to have such registration statement(s) declared effective as promptly as possible thereafter, and in any event no later than 60 days following June 23, 2024, or, in the event of a full review by the SEC, 90 days following June 23, 2024.
• The company expects to use the net proceeds from the exercise of any Warrants for working capital and general corporate purposes, including to continue the clinical development of DA-1726 for the treatment of obesity.

Key Dates

Keywords

NeuroBo Pharmaceuticals, common stock, registration statement, resale, warrants, MASH, obesity, DA-1241, DA-1726, clinical trials, private placement, selling securityholders